Is Apple Stock Undervalued or Overvalued?
For many years, Apple (NASDAQ:AAPL) was just about the perfect…
Sell
48
SYNB Quote, Financials, Valuation and Earnings
Last price:
$27.41
Seasonality move
:
2.75%
Day range:
$27.82 - $27.82
52-week range:
$24.57 - $33.23
Dividend yield:
0.77%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
2
Avg. volume:
123
1-year change:
-9.99%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SYNB
Putnam BioRevolution ETF
|
-- | -- | -- | -- | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
-- | -- | -- | -- | -- |
|
OZEM
Roundhill GLP-1 & Weight Loss ETF
|
-- | -- | -- | -- | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SYNB
Putnam BioRevolution ETF
|
$27.82 | -- | -- | -- | $0.21 | 0.77% | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
$49.64 | -- | -- | -- | $0.33 | 5.67% | -- |
|
OZEM
Roundhill GLP-1 & Weight Loss ETF
|
$24.71 | -- | -- | -- | $0.05 | 0% | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
$22.07 | -- | -- | -- | $0.22 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SYNB
Putnam BioRevolution ETF
|
-- | 1.058 | -- | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
-- | 0.940 | -- | -- |
|
OZEM
Roundhill GLP-1 & Weight Loss ETF
|
-- | 0.000 | -- | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SYNB
Putnam BioRevolution ETF
|
-- | -- | -- | -- | -- | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
-- | -- | -- | -- | -- | -- |
|
OZEM
Roundhill GLP-1 & Weight Loss ETF
|
-- | -- | -- | -- | -- | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | -- | -- | -- | -- | -- |
Putnam BioRevolution ETF vs. Competitors
-
Which has Higher Returns SYNB or JDOC?
JPMorgan Healthcare Leaders ETF has a net margin of -- compared to Putnam BioRevolution ETF's net margin of --. Putnam BioRevolution ETF's return on equity of -- beat JPMorgan Healthcare Leaders ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SYNBPutnam BioRevolution ETF-- -- -- JDOCJPMorgan Healthcare Leaders ETF-- -- -- -
What do Analysts Say About SYNB or JDOC?
Putnam BioRevolution ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand JPMorgan Healthcare Leaders ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Putnam BioRevolution ETF has higher upside potential than JPMorgan Healthcare Leaders ETF, analysts believe Putnam BioRevolution ETF is more attractive than JPMorgan Healthcare Leaders ETF.
Company Buy Ratings Hold Ratings Sell Ratings SYNBPutnam BioRevolution ETF0 0 0 JDOCJPMorgan Healthcare Leaders ETF0 0 0 -
Is SYNB or JDOC More Risky?
Putnam BioRevolution ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison JPMorgan Healthcare Leaders ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SYNB or JDOC?
Putnam BioRevolution ETF has a quarterly dividend of $0.21 per share corresponding to a yield of 0.77%. JPMorgan Healthcare Leaders ETF offers a yield of 5.67% to investors and pays a quarterly dividend of $0.33 per share. Putnam BioRevolution ETF pays -- of its earnings as a dividend. JPMorgan Healthcare Leaders ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYNB or JDOC?
Putnam BioRevolution ETF quarterly revenues are --, which are smaller than JPMorgan Healthcare Leaders ETF quarterly revenues of --. Putnam BioRevolution ETF's net income of -- is lower than JPMorgan Healthcare Leaders ETF's net income of --. Notably, Putnam BioRevolution ETF's price-to-earnings ratio is -- while JPMorgan Healthcare Leaders ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Putnam BioRevolution ETF is -- versus -- for JPMorgan Healthcare Leaders ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYNBPutnam BioRevolution ETF-- -- -- -- JDOCJPMorgan Healthcare Leaders ETF-- -- -- --
-
Which has Higher Returns SYNB or OZEM?
Roundhill GLP-1 & Weight Loss ETF has a net margin of -- compared to Putnam BioRevolution ETF's net margin of --. Putnam BioRevolution ETF's return on equity of -- beat Roundhill GLP-1 & Weight Loss ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SYNBPutnam BioRevolution ETF-- -- -- OZEMRoundhill GLP-1 & Weight Loss ETF-- -- -- -
What do Analysts Say About SYNB or OZEM?
Putnam BioRevolution ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Roundhill GLP-1 & Weight Loss ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Putnam BioRevolution ETF has higher upside potential than Roundhill GLP-1 & Weight Loss ETF, analysts believe Putnam BioRevolution ETF is more attractive than Roundhill GLP-1 & Weight Loss ETF.
Company Buy Ratings Hold Ratings Sell Ratings SYNBPutnam BioRevolution ETF0 0 0 OZEMRoundhill GLP-1 & Weight Loss ETF0 0 0 -
Is SYNB or OZEM More Risky?
Putnam BioRevolution ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Roundhill GLP-1 & Weight Loss ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SYNB or OZEM?
Putnam BioRevolution ETF has a quarterly dividend of $0.21 per share corresponding to a yield of 0.77%. Roundhill GLP-1 & Weight Loss ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.05 per share. Putnam BioRevolution ETF pays -- of its earnings as a dividend. Roundhill GLP-1 & Weight Loss ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYNB or OZEM?
Putnam BioRevolution ETF quarterly revenues are --, which are smaller than Roundhill GLP-1 & Weight Loss ETF quarterly revenues of --. Putnam BioRevolution ETF's net income of -- is lower than Roundhill GLP-1 & Weight Loss ETF's net income of --. Notably, Putnam BioRevolution ETF's price-to-earnings ratio is -- while Roundhill GLP-1 & Weight Loss ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Putnam BioRevolution ETF is -- versus -- for Roundhill GLP-1 & Weight Loss ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYNBPutnam BioRevolution ETF-- -- -- -- OZEMRoundhill GLP-1 & Weight Loss ETF-- -- -- --
-
Which has Higher Returns SYNB or THNR?
Amplify Weight Loss Drug & Treatment ETF has a net margin of -- compared to Putnam BioRevolution ETF's net margin of --. Putnam BioRevolution ETF's return on equity of -- beat Amplify Weight Loss Drug & Treatment ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SYNBPutnam BioRevolution ETF-- -- -- THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- -
What do Analysts Say About SYNB or THNR?
Putnam BioRevolution ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Amplify Weight Loss Drug & Treatment ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Putnam BioRevolution ETF has higher upside potential than Amplify Weight Loss Drug & Treatment ETF, analysts believe Putnam BioRevolution ETF is more attractive than Amplify Weight Loss Drug & Treatment ETF.
Company Buy Ratings Hold Ratings Sell Ratings SYNBPutnam BioRevolution ETF0 0 0 THNRAmplify Weight Loss Drug & Treatment ETF0 0 0 -
Is SYNB or THNR More Risky?
Putnam BioRevolution ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SYNB or THNR?
Putnam BioRevolution ETF has a quarterly dividend of $0.21 per share corresponding to a yield of 0.77%. Amplify Weight Loss Drug & Treatment ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.22 per share. Putnam BioRevolution ETF pays -- of its earnings as a dividend. Amplify Weight Loss Drug & Treatment ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYNB or THNR?
Putnam BioRevolution ETF quarterly revenues are --, which are smaller than Amplify Weight Loss Drug & Treatment ETF quarterly revenues of --. Putnam BioRevolution ETF's net income of -- is lower than Amplify Weight Loss Drug & Treatment ETF's net income of --. Notably, Putnam BioRevolution ETF's price-to-earnings ratio is -- while Amplify Weight Loss Drug & Treatment ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Putnam BioRevolution ETF is -- versus -- for Amplify Weight Loss Drug & Treatment ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYNBPutnam BioRevolution ETF-- -- -- -- THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Palo Alto Networks Stock Be in 5 Years?
You know those companies that just refuse to slow down…
UPS Stock Forecast: Is the 6.9% Dividend Too Good to Be True?
Parcel delivery giant UPS (NYSE:UPS) has seen its fair share…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
68
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
58
TNXP alert for May 28
Tonix Pharmaceuticals Holding [TNXP] is up 1.57% over the past day.
Sell
37
ATS alert for May 28
ATS [ATS] is down 1.27% over the past day.
Buy
88
SMR alert for May 28
NuScale Power [SMR] is down 0.37% over the past day.
